For HCC patients with high Alpha-fetoprotein (AFP) level (≥ 400ng/mL) recurrence risk, according to the survival analysis of different adjuvant treatment regimens, there was a significant difference in OS between the LR group, the TACE treatment group and the TKI treatment group (Figure 4A), while the difference in DFS was not significant (Figure 4B). Here, AFP is linked to hepatocellular carcinoma.